Breaking News

Glaxo to Pay $488.7 Million Fine to End China Corruption Probe
Tweet TWEET

CTI Announces Data Presentations at the 18th Congress of the European Hematology Association

    CTI Announces Data Presentations at the 18th Congress of the European
                            Hematology Association

PR Newswire

SEATTLE, June 11, 2013

SEATTLE, June 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ
and MTA: CTIC) today announced the upcoming presentation of data highlighting
PIXUVRI^® (pixantrone), the first approved treatment in the European Union for
aggressive B-cell non-Hodgkin lymphoma (NHL) for adult patients who have
failed 2 to 3 prior lines of therapy, and results from a pooled analysis of
data from completed Phase 1 and 2 studies of pacritinib, a novel, oral
JAK2/FLT3 inhibitor, at the 18^th Congress of the European Hematology
Association (EHA) Annual Meeting, June 13-16, 2013 in Stockholm, Sweden.

"At EHA, we plan to present further analyses of the final safety and efficacy
data from our EXTEND pivotal trial of PIXUVRI that we believe expand our
understanding of the potential clinical benefit for patients with aggressive
B-cell NHL who had received 2 to 3 prior regimens," said Jack Singer, M.D.,
Executive Vice President, Global Medical Affairs and Translational Medicine at
CTI. "In addition, at EHA, results from a pooled integrated safety analysis
from four Phase 1 and 2 clinical trials will be presented that quantify
clinical toxicities of pacritinib, our novel, oral JAK2/FLT3 inhibitor
currently being investigated in a Phase 3 clinical program."

Information regarding the EHA presentations is below. Full abstracts can be
viewed at the EHA website.

Abstract Number: P310
Poster Title: Pixantrone monotherapy in histologically confirmed, relapsed or
refractory aggressive B-cell non-Hodgkin lymphoma: Post-hoc analyses from a
Phase 3 trial
Presentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST,
Poster Hall
First Author: Dr. Ruth Pettengell, St. George's Hospital, London, United
Kingdom

Abstract Number: P278
Poster Title: Safety overview of phase I-II studies of pacritinib, a
non-myelosuppressive JAK2/FLT3 inhibitor, in patients with hematological
malignancies
Presentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST,
Poster Hall
First Author: Dr. S. Verstovsek, MD Anderson Cancer Center, Houston, United
States

Abstract Number: P983
Poster Title: Characterization of the pharmacokinetic and pharmacodynamic
properties of pacritinib, a novel oral JAK2/FLT3 inhibitor, in patients with
myelofibrosis, AML and lymphoma
Presentation Date/Time/Location: Poster session, Saturday, June 15, 5:45 to
7:00 p.m. CEST, Poster Hall
First Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Seattle, United
States

About PIXUVRI (pixantrone)

PIXUVRI is a novel aza-anthracenedione with unique structural and
physiochemical properties. Unlike related compounds,PIXUVRI forms stable DNA
adducts and in preclinical models has superior anti-lymphoma activity compared
to related compounds. PIXUVRI was structurally designed so that it cannot bind
iron and perpetuate oxygen radical production or form a long-lived hydroxyl
metabolite -- both of which are the putative mechanisms for anthracycline
induced acute and chronic cardiotoxicity. These novel pharmacologic properties
allow PIXUVRI to be administered to patients with near maximal lifetime
exposure to anthracyclines without unacceptable rates of cardiotoxicity.

InMay 2012, the European Commission granted conditional marketing
authorization for PIXUVRI as a monotherapy for the treatment of adult patients
with multiply relapsed or refractory aggressiveNHL based on the results of
the EXTEND, or PIX301, pivotal randomized Phase 3 clinical trial. The benefit
of PIXUVRI treatment has not been established in patients when used as fifth
line or greater chemotherapy in patients who are refractory to last
therapy.The Summary of Product Characteristics (SmPC) has the full
prescribing information, including the safety and efficacy profile of PIXUVRI
in the approved indication. TheSmPCis available atwww.pixuvri.eu. CTI is
currently accruing patients into a Phase 3 trial comparing PIXUVRI and
rituximab with gemcitabine and rituximab in the setting of aggressive B-cell
NHL. PIXUVRI does not have marketing approval inthe United States.

About Pacritinib

Pacritinib is an oral, once-a-day, tyrosine kinase inhibitor (TKI) with dual
activity against JAK2 and FLT3. The JAK family of enzymes are a central
component in signal transduction pathways, which are critical to normal blood
cell growth and development as well as inflammatory cytokine expression and
immune responses. Mutations in these kinases have been shown to be directly
related to the development of a variety of blood related cancers including
myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an
advantage over other JAK inhibitors through effective treatment of symptoms
while having less treatment-emergent thrombocytopenia and anemia than has been
seen in currently approved and in-development JAK inhibitors. Pacritinib has
demonstrated encouraging results in Phase 1 and 2 studies for patients with
myelofibrosis. Pacritinib has orphan drug designation in the U.S. and Europe.

AboutCell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the
development and commercialization of an integrated portfolio of oncology
products aimed at making cancer more treatable. CTI is headquartered
inSeattle, WA.For additional information and to sign up for email alerts and
get RSS feeds, please visitwww.CellTherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number
of risks and uncertainties, the outcome of which could materially and/or
adversely affect actual future results and the market price of CTI's
securities. Specifically, the risks and uncertainties that could affect the
development of PIXUVRI and pacritinib include risks associated with
preclinical and clinical developments in the biopharmaceutical industry in
general and with PIXUVRI and pacritinib in particular including, without
limitation, the potential failure of PIXUVRI to prove safe and effective for
the treatment of relapsed or refractory NHL and/or other tumors as determined
by the U.S. Food and Drug Administration (FDA); that results in future studies
of PIXUVRI may differ from the results of past studies; that CTI may not be
able to complete the PIX306 clinical trial of PIXUVRI-rituximab compared to
gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior
regimens for aggressive B-cellNHL and who are not eligible for autologous
stem cell transplant byJune 2015or at all as required by the European
Medicines Agency (EMA) or have the results of such trial available byJune
2015or at all; that CTI may not be able complete a post-marketing study aimed
at confirming the clinical benefit of PIXUVRI that was observed in the PIX301
trial; that the conditional marketing authorization for PIXUVRI may not be
renewed; the potential failure of pacritinib to prove safe and effective for
the treatment of patients with myelofibrosis, either alone or in combination
regimens, as determined by the FDA and/or EMA; that pacritinib may not satisfy
a medical need not currently addressed with existing non-selective JAK1/JAK2
inhibitors; that the Phase III clinical trials of pacritinib may not occur as
planned; that CTI may not be able to successfully implement its plans,
strategies and objectives related to the development of pacritinib; that CTI
cannot predict or guarantee the pace or geography of enrollment of its
clinical trials or the total number of patients enrolled; that CTI's average
net operating burn rate may increase; CTI's may not be able to continue to
raise capital as needed to fund its operations in general, and other risks,
including, without limitation, competitive factors, technological
developments, costs of developing, producing, and selling PIXUVRI and
pacritinib, and the risk factors listed or described from time to time in
CTI's filings with theSecurities and Exchange Commissionincluding, without
limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as
may be required by law, CTI does not intend to update or alter its
forward-looking statements whether as a result of new information, future
events, or otherwise.

References:
1. European Cancer Observatory, Cancer Fact Sheets, 2008
2. Harris NL, et al. Ann Oncol. 1999;10(12):1419-32
3. Friedberg ASH Education Book 2011;1:498-505

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.



CTI Media and Investor Contacts:
Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
invest@ctiseattle.com

In Europe
CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
F: +39 02 89659719
http://www.celltherapeutics.com/italiano

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.